MDM2 and acute myeloid leukemia: Many studies have shown the efficacy of MDM2 inhibitors in preclinical models of AML, either alone or combined with various inhibitors, including those targeting the mitogen-activated protein kinase pathway (Long et al, 2010; Zang et al, 2010; Weisberg et al, 2015; Lehmann et al, 2016).